Altimmune Statistics
Total Valuation
Altimmune has a market cap or net worth of $320.10 million. The enterprise value is $91.24 million.
| Market Cap | 320.10M |
| Enterprise Value | 91.24M |
Important Dates
The last earnings date was Thursday, November 12, 2026, before market open.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Altimmune has 194.59 million shares outstanding. The number of shares has increased by 95.66% in one year.
| Current Share Class | 194.59M |
| Shares Outstanding | 194.59M |
| Shares Change (YoY) | +95.66% |
| Shares Change (QoQ) | +10.69% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 61.73% |
| Float | 164.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12,311.52 |
| Forward PS | n/a |
| PB Ratio | 0.72 |
| P/TBV Ratio | 0.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3,509.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.93, with a Debt / Equity ratio of 0.08.
| Current Ratio | 23.93 |
| Quick Ratio | 23.31 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.29 |
Financial Efficiency
Return on equity (ROE) is -33.17% and return on invested capital (ROIC) is -20.84%.
| Return on Equity (ROE) | -33.17% |
| Return on Assets (ROA) | -19.88% |
| Return on Invested Capital (ROIC) | -20.84% |
| Return on Capital Employed (ROCE) | -23.46% |
| Weighted Average Cost of Capital (WACC) | 5.46% |
| Revenue Per Employee | $456 |
| Profits Per Employee | -$1.83M |
| Employee Count | 57 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.11% in the last 52 weeks. The beta is 0.15, so Altimmune's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | -61.11% |
| 50-Day Moving Average | 2.58 |
| 200-Day Moving Average | 3.13 |
| Relative Strength Index (RSI) | 26.49 |
| Average Volume (20 Days) | 3,850,303 |
Short Selling Information
The latest short interest is 42.13 million, so 21.65% of the outstanding shares have been sold short.
| Short Interest | 42.13M |
| Short Previous Month | 42.23M |
| Short % of Shares Out | 21.65% |
| Short % of Float | 25.64% |
| Short Ratio (days to cover) | 10.98 |
Income Statement
In the last 12 months, Altimmune had revenue of $26,000 and -$104.35 million in losses. Loss per share was -$0.67.
| Revenue | 26,000 |
| Gross Profit | -78.75M |
| Operating Income | -113.58M |
| Pretax Income | -104.35M |
| Net Income | -104.35M |
| EBITDA | -113.50M |
| EBIT | -113.58M |
| Loss Per Share | -$0.67 |
Balance Sheet
The company has $265.06 million in cash and $36.20 million in debt, with a net cash position of $228.86 million or $1.18 per share.
| Cash & Cash Equivalents | 265.06M |
| Total Debt | 36.20M |
| Net Cash | 228.86M |
| Net Cash Per Share | $1.18 |
| Equity (Book Value) | 443.57M |
| Book Value Per Share | 2.28 |
| Working Capital | 264.24M |
Cash Flow
In the last 12 months, operating cash flow was -$102.36 million and capital expenditures -$118,000, giving a free cash flow of -$102.47 million.
| Operating Cash Flow | -102.36M |
| Capital Expenditures | -118,000 |
| Depreciation & Amortization | 83,000 |
| Net Borrowing | 20.73M |
| Free Cash Flow | -102.47M |
| FCF Per Share | -$0.53 |
Margins
| Gross Margin | n/a |
| Operating Margin | -436,842.31% |
| Pretax Margin | -401,361.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Altimmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -95.66% |
| Shareholder Yield | -95.66% |
| Earnings Yield | -40.80% |
| FCF Yield | -32.01% |
Analyst Forecast
The average price target for Altimmune is $16.33, which is 892.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.33 |
| Price Target Difference | 892.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 314.91% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on September 14, 2018. It was a reverse split with a ratio of 1:30.
| Last Split Date | Sep 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Altimmune has an Altman Z-Score of 3.79 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.79 |
| Piotroski F-Score | 3 |